Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 14;29(5):1103–1112. doi: 10.1038/s41591-023-02321-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — Efficacy evaluable population: Primary and expansion cohorts in all except low grade glioma and MM which is primary analysis cohort; (A) Investigator assessment (B) Independent radiology assessment. ATC: By investigator assessment in 36 patients, 21 (58%) patients had disease progression and six (17%) had died without disease progression. Nine (25%) patients were censored due to end of follow-up. By independent radiology review, progression of disease was observed in 26 (72%) patients and three (8%) patients died without disease progression. Seven (19%) patients were censored due to end of follow-up. BTC: By investigator assessment in 43 patients, 33 (77%) patients had disease progression and six (14%) patients had died without disease progression. Four patients were censored due to end of follow-up. By independent radiology review, progression of disease was observed in 27 (63%) patients and five (12%) patients died without disease progression. Eleven (26%) patients were censored due to end of follow-up. ASI: By investigator assessment in three patients, one patient (33%) had disease progression. Two (67%) patients were censored due to end of follow-up. By independent radiology review, progression of disease was observed in three (100%) patients. LGG: By investigator assessment in 13 patients, six (46%) patients had disease progression. Seven (54%) patients were censored due to end of follow-up. By independent radiology review, progression of disease was observed in nine (69%) patients and one (8%) patient died without disease progression. Three (23%) patients were censored due to end of follow-up. HGG: By investigator assessment in 45 patients, 38 (84%) patients had disease progression. Seven (16%) patients were censored due to end of follow-up. By independent radiology review, progression of disease was observed in 36 (80%) patients and four (9%) patients died without disease progression. Five (11%) patients were censored due to end of follow-up. HCL: By investigator assessment in 55 subjects, six (11%) patients had disease progression and three (5%) patients had died without disease progression. Forty-six (84%) patients were censored due to end of follow-up. MM: By investigator assessment in 10 patients, nine (90%) patients had disease progression. One patient was censored due to end of follow-up. ASI, adenocarcinoma of small intestine; ATC, anaplastic thyroid cancer; BTC, biliary tract cancer; G, grade; HCL, hairy cell leukemia; HGG, high (WHO G3/G4) grade glioma; LGG, low (WHO G1/G2) grade glioma; MM, multiple myeloma; WHO, World Health Organization.